Last edition
News about Clinical Trials
Pfizer has announced positive topline results from its Phase 3 HER2CLIMB-05 trial evaluating TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for patients with HER2-positive (HER2+) metastatic breast cancer (MBC).
Clinical Trials | 15/10/2025 | By Dineshwori | 286
AskBio Reports Safety Data from AB-1003 LGMD 2I/R9 Study
Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with Limb-Girdle Muscular Dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or serious adverse events reported up to 52 weeks post-treatment.
Clinical Trials | 13/10/2025 | By Dineshwori | 233
Lupin to Present Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025
Lupin will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled to be held from October 17 to October 21, 2025.
Clinical Trials | 13/10/2025 | By Dineshwori | 318
Merck is set to showcase new data at ESMO 2025, highlighting advancements in oncology across emerging tumor types and early-stage diseases, with positive survival results from KEYNOTE-905 and KEYNOTE-B96 trials demonstrating the impact of KEYTRUDA (pembrolizumab) in bladder and ovarian cancers.
Clinical Trials | 11/10/2025 | By Dineshwori | 970
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
Clinical Trials | 11/10/2025 | By Dineshwori | 918
Sanofi and Partners Report Positive Phase 2 Results for AlphaMedix in Advanced GEP-NETs
AlphaMedix, which is developed by Orano Med and RadioMedix and now licensed to Sanofi, achieved all primary efficacy endpoints in the phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumours.
Clinical Trials | 08/10/2025 | By Dineshwori | 502
UK Halves Clinical Trial Approval Times Through Major Digital Reforms
Backed by major reforms and new digital platforms at the Medicines and Healthcare products Regulatory Agency (MHRA), the UK has reduced the average clinical trial approval time by more than half — from 91 days to just 41 days.
Clinical Trials | 08/10/2025 | By Dineshwori | 285
WHO launches Global Clinical Trials Forum
The Forum responds to World Health Assembly resolution WHA75.8, which called on WHO to improve the quality and coordination of clinical trials to generate high-quality evidence for health decision-making.
Clinical Trials | 08/10/2025 | By Dineshwori | 211
Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases
Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.
Clinical Trials | 07/10/2025 | By Dineshwori | 550
Onco3R Therapeutics Advances Phase 1 Trial of Novel SIK3 Inhibitor Targeting Autoimmune Diseases
Pierre Raboisson, CEO and Founder of Onco3R Therapeutics, said that the final results of the Phase 1 trial of O3R-5671 are expected in the first half of 2026.
Clinical Trials | 06/10/2025 | By Dineshwori | 295
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy